Journey Study

About Schizophrenia

Schizophrenia is a complex disorder and is not well understood. 

Researchers believe that a combination of genetics and environment contributes to its development and problems with certain naturally occurring brain chemicals, may also be contributors. 

Current treatment options include different antipsychotic medications.


Research is underway on a study drug for individuals who still experience symptoms despite treatment. 

Our recent project 

It is a 16-week study that will evaluate the effect of adjunctive Valbenazine vs placebo on symptoms of schizophrenia in subjects who have an inadequate response to antipsychotic treatment.

The purpose of this study is to evaluate if the study drug, may help with schizophrenia symptoms compared to placebo (a substance that looks like Valbenzine but does not contain active drug)

Your time and effort will be financially rewarded.

You can withdraw at any time, for any reason you want.

You may be eligible if you are: 


13 years or older

Receiving antipsychotic therapy

(Other than clozapine)

Diagnosed with schizophrenia

at least 1 year ago

Treated with a stable regimen antipsychotic medication 

With no 

meaningful change

Download the Journey 2 material and take it with you:

Meet our other studies!

ADEPT-1 Study

Evaluating the safety and efficacy of KarXT, an investigational drug, for the treatment of psychosis associated with Alzheimer’s disease dementia.


Evaluating the effectiveness of the investigational medication, Luvadaxistat, in individuals with schizophrenia, to improve their cognitive function.


Evaluating an investigational medication for individuals with schizophrenia who have had an inadequate response to antipsychotic medication.